1. Home
  2. GBIO vs ATLO Comparison

GBIO vs ATLO Comparison

Compare GBIO & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • ATLO
  • Stock Information
  • Founded
  • GBIO 2016
  • ATLO 1903
  • Country
  • GBIO United States
  • ATLO United States
  • Employees
  • GBIO N/A
  • ATLO N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • GBIO Health Care
  • ATLO Finance
  • Exchange
  • GBIO Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • GBIO 29.2M
  • ATLO 158.4M
  • IPO Year
  • GBIO 2020
  • ATLO N/A
  • Fundamental
  • Price
  • GBIO $0.39
  • ATLO $18.10
  • Analyst Decision
  • GBIO Strong Buy
  • ATLO
  • Analyst Count
  • GBIO 4
  • ATLO 0
  • Target Price
  • GBIO $7.33
  • ATLO N/A
  • AVG Volume (30 Days)
  • GBIO 1.1M
  • ATLO 18.1K
  • Earning Date
  • GBIO 08-06-2025
  • ATLO 08-08-2025
  • Dividend Yield
  • GBIO N/A
  • ATLO 4.35%
  • EPS Growth
  • GBIO N/A
  • ATLO 14.69
  • EPS
  • GBIO N/A
  • ATLO 1.27
  • Revenue
  • GBIO $24,556,000.00
  • ATLO $55,041,000.00
  • Revenue This Year
  • GBIO N/A
  • ATLO N/A
  • Revenue Next Year
  • GBIO N/A
  • ATLO N/A
  • P/E Ratio
  • GBIO N/A
  • ATLO $14.29
  • Revenue Growth
  • GBIO 146.47
  • ATLO 6.77
  • 52 Week Low
  • GBIO $0.30
  • ATLO $15.69
  • 52 Week High
  • GBIO $3.65
  • ATLO $22.03
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 52.02
  • ATLO 59.86
  • Support Level
  • GBIO $0.32
  • ATLO $18.16
  • Resistance Level
  • GBIO $0.36
  • ATLO $18.68
  • Average True Range (ATR)
  • GBIO 0.03
  • ATLO 0.34
  • MACD
  • GBIO 0.00
  • ATLO 0.08
  • Stochastic Oscillator
  • GBIO 81.00
  • ATLO 83.13

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.

Share on Social Networks: